Skip to main content

VedTechBio Research Pvt. Ltd.

Accelerating Oral Drug Discovery in Cardio Metabolic Disease: From Biology to Validated Small Molecule Candidates

  • Success Story

Context & Objective

  • RenaissThera is advancing next-generation oral small molecule therapies for cardio-metabolic diseases such as diabetes and obesity.
  • Redefining cardio-metabolic care through oral small-molecule innovation, the company is building next-generation alternatives to injectable peptide therapies, targeting pathways such as GLP-1 and GIP to improve patient access while reducing long-term treatment costs.
  • To accelerate early discovery and minimize risk, RenaissThera partnered with us to transform complex biological hypotheses into experimentally validated drug candidates, leveraging our AI-driven drug design capabilities and deep domain expertise in cardio metabolic biology.

Approach & Solution

  • We implemented a custom, end-to-end discovery program that seamlessly integrated advanced AI platforms with biology-led experimental validation.
  • Our multidisciplinary team across medicinal chemistry, molecular biology, bioinformatics, and data science applied machine learning models to rapidly design and prioritize novel drug-like small molecules based on binding potential.
  • Every AI-generated molecule underwent rigorous expert review to ensure synthetic feasibility, medicinal chemistry excellence, and alignment with program objectives.
  • Our biologists designed and executed purpose-built in vitro assays to confirm target engagement and functional activity, ensuring AI-generated hypotheses translated into robust biological signals.
  • Early in vivo pharmacology studies in disease-relevant models validated functional efficacy, providing confidence that prioritized candidates were both biologically meaningful and development-ready.
  • The integrated AI to assay strategy delivered multiple validated oral small molecule candidates aligned with RenaissThera’s cardio metabolic pipeline.

Outcome & Impact

By combining strategic consulting, AI-driven molecular design platforms, and deep expertise in cardio-metabolic biology and assay development, we significantly accelerated discovery timelines, reduced early-stage risk, and enabled RenaissThera to decisively advance experimentally validated oral small-molecule candidates into lead optimization.